Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

14.79 -0.24 (-1.63%)
Streaming Delayed Price Updated: 10:05 AM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Takeda Says 'Human Error' Reason Behind Contaminated Moderna COVID-19 Vaccines
Takeda Pharmaceutical Co Ltd (NYSE: TAK) blamed "human error" as the cause of metal contaminants found in some batches of Moderna Inc's (NASDAQ: MRNA... 
Via Benzinga
September Ends
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
Takeda In-Licenses Hunter Syndrome Candidate
Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to... 
Via Benzinga
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in... 
Via Benzinga
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Mirum, Takeda Ink Maralixibat Licensing Pact In Japan
Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for... 
Via Benzinga
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
From Mirum Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Takeda's Exkivity Scores FDA Nod As First Oral Therapy For Lung Cancer With EGFR Exon20 Insertion
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Exkivity (mobocertinib) for non-small cell lung cancer (NSCLC) settings. The approval comes for... 
Via Benzinga
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
ADHD Drug Developer Cingulate Plans NASDAQ Debut
Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention... 
Via Benzinga
Topics Initial Public Offering
Why Novavax Stock Is Slipping Again Today
A reported delay in India's EUA for Novavax's COVID-19 vaccine appears to still be weighing on the stock. 
Via The Motley Fool
Why Novavax Stock Surged Today
The biotech's coronavirus-related revenue could be about to soar. 
Via The Motley Fool
NVAX Stock: The Big Reason Why Novavax Shares Are Gaining Today
A Japanese pharma giant has partnered with Novavax to supply millions of vaccines. NVAX stock is reacting accordingly. 
Via InvestorPlace
Novavax Shares Surge On Vaccine Supply Deal With Japan
Novavax, Inc. shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. 
Via Talk Markets
Novavax Shares Surge On Vaccine Supply Deal With Japan
Novavax, Inc. (NASDAQ: NVAX) shares were trading higher Tuesday following the signing of a coronavirus vaccine supply deal. What Happened: Japanese pharma giant Takeda... 
Via Benzinga
Mu - The Newest Worry
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced topline data from the Phase 3 PANTHER study evaluating pevonedistat in blood cancer indications. The trial did... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna Reviews Contamination In Vaccine Lot Distributed In Japan
Moderna, Inc. (NASDAQ: MRNA) found itself in a controversy after Japan suspended the use of about 2.6 million doses of the company's COVID-19 vaccine following reports of... 
Via Benzinga
UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma
New guidance from the National Institute for Health and Care Excellence (NICE) has rejected a combination regimen based on Johnson & Johnson's (NYSE: JNJ)... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.